Skip to main content
Top
Published in: BMC Infectious Diseases 1/2014

Open Access 01-12-2014 | Research article

Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia

Authors: Agnes Loo Yee Cheah, Trisha Peel, Benjamin P Howden, Denis Spelman, M Lindsay Grayson, Roger L Nation, David CM Kong

Published in: BMC Infectious Diseases | Issue 1/2014

Login to get access

Abstract

Background

Enterococci are a major cause of healthcare-associated infection. In Australia, vanB vancomycin-resistant enterococci (VRE) is the predominant genotype. There are limited data on the factors linked to vanB VRE bacteraemia. This study aimed to identify factors associated with vanB VRE bacteraemia, and compare them with those for vancomycin-susceptible enterococci (VSE) bacteraemia.

Methods

A case-case-control study was performed in two tertiary public hospitals in Victoria, Australia. VRE and VSE bacteraemia cases were compared with controls without evidence of enterococcal bacteraemia, but may have had infections due to other pathogens.

Results

All VRE isolates had vanB genotype. Factors associated with vanB VRE bacteraemia were urinary catheter use within the last 30 days (OR 2.86, 95% CI 1.09-7.53), an increase in duration of metronidazole therapy (OR 1.65, 95% CI 1.17-2.33), and a higher Chronic Disease Score specific for VRE (OR 1.70, 95% CI 1.05-2.77). Factors linked to VSE bacteraemia were a history of gastrointestinal disease (OR 2.29, 95% CI 1.05-4.99) and an increase in duration of metronidazole therapy (OR 1.23, 95% CI 1.02-1.48). Admission into the haematology/oncology unit was associated with lower odds of VSE bacteraemia (OR 0.08, 95% CI 0.01-0.74).

Conclusions

This is the largest case-case-control study involving vanB VRE bacteraemia. Factors associated with the development of vanB VRE bacteraemia were different to those of VSE bacteraemia.
Literature
1.
go back to reference Hidron Alicia I, Edwards Jonathan R, Patel J, Horan Teresa C, Sievert Dawn M, Pollock Daniel A, Fridkin Scott K: NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2006–2007. Infect Control Hosp Epidemiol. 2008, 29: 996-1011. 10.1086/591861.CrossRefPubMed Hidron Alicia I, Edwards Jonathan R, Patel J, Horan Teresa C, Sievert Dawn M, Pollock Daniel A, Fridkin Scott K: NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2006–2007. Infect Control Hosp Epidemiol. 2008, 29: 996-1011. 10.1086/591861.CrossRefPubMed
2.
go back to reference Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN: Antimicrobial resistance and molecular epidemiology of vancomycin-resistant Enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007, 58: 163-170. 10.1016/j.diagmicrobio.2006.12.022.CrossRefPubMed Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN: Antimicrobial resistance and molecular epidemiology of vancomycin-resistant Enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007, 58: 163-170. 10.1016/j.diagmicrobio.2006.12.022.CrossRefPubMed
4.
go back to reference Webb M, Riley L, Roberts R: Cost of hospitalization for and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization. Clin Infect Dis. 2001, 33: 445-452. 10.1086/321891.CrossRefPubMed Webb M, Riley L, Roberts R: Cost of hospitalization for and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization. Clin Infect Dis. 2001, 33: 445-452. 10.1086/321891.CrossRefPubMed
5.
go back to reference Bell JM, Paton JC, Turnidge J: Emergence of vancomycin-resistant Enterococci in Australia: phenotypic and genotypic characteristics of isolates. J Clin Microbiol. 1998, 36: 2187-2190.PubMedPubMedCentral Bell JM, Paton JC, Turnidge J: Emergence of vancomycin-resistant Enterococci in Australia: phenotypic and genotypic characteristics of isolates. J Clin Microbiol. 1998, 36: 2187-2190.PubMedPubMedCentral
6.
go back to reference Schouten MA, Hoogkamp-Korstanje JA, Meis JF, Voss A: Prevalence of vancomycin-resistant enterococci in Europe. Eur J Clin Microbiol Infect Dis. 2000, 19: 816-822. 10.1007/s100960000390.CrossRefPubMed Schouten MA, Hoogkamp-Korstanje JA, Meis JF, Voss A: Prevalence of vancomycin-resistant enterococci in Europe. Eur J Clin Microbiol Infect Dis. 2000, 19: 816-822. 10.1007/s100960000390.CrossRefPubMed
7.
go back to reference Stuart RL, Kotsanas D, Webb B, Vandergraaf S, Gillespie EE, Hogg GG, Korman TM: Prevalence of antimicrobial-resistant organisms in residential aged care facilities. Med J Aust. 2011, 195: 530-533. 10.5694/mja11.10724.CrossRefPubMed Stuart RL, Kotsanas D, Webb B, Vandergraaf S, Gillespie EE, Hogg GG, Korman TM: Prevalence of antimicrobial-resistant organisms in residential aged care facilities. Med J Aust. 2011, 195: 530-533. 10.5694/mja11.10724.CrossRefPubMed
8.
go back to reference Burrell LJ, Grabsch EA, Padiglione AA, Grayson ML: Prevalence of colonisation with vancomycin-resistant enterococci (VRE) among haemodialysis outpatients in Victoria: implications for screening. Med J Aust. 2005, 182: 492-PubMed Burrell LJ, Grabsch EA, Padiglione AA, Grayson ML: Prevalence of colonisation with vancomycin-resistant enterococci (VRE) among haemodialysis outpatients in Victoria: implications for screening. Med J Aust. 2005, 182: 492-PubMed
9.
go back to reference Montecalvo MA, Horowitz H, Gedris C, Carbonaro C, Tenover FC, Issah A, Cook P, Wormser GP: Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother. 1994, 38: 1363-1367. 10.1128/AAC.38.6.1363.CrossRefPubMedPubMedCentral Montecalvo MA, Horowitz H, Gedris C, Carbonaro C, Tenover FC, Issah A, Cook P, Wormser GP: Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother. 1994, 38: 1363-1367. 10.1128/AAC.38.6.1363.CrossRefPubMedPubMedCentral
10.
go back to reference Edmond MB, Ober JF, Weinbaum DL, Pfaller MA, Hwang T, Sanford MD, Wenzel RP: Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis. 1995, 20: 1126-1133. 10.1093/clinids/20.5.1126.CrossRefPubMed Edmond MB, Ober JF, Weinbaum DL, Pfaller MA, Hwang T, Sanford MD, Wenzel RP: Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis. 1995, 20: 1126-1133. 10.1093/clinids/20.5.1126.CrossRefPubMed
11.
go back to reference Shay DK, Maloney SA, Montecalvo M, Banerjee S, Wormser GP, Arduino MJ, Bland LA, Jarvis WR: Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis. 1995, 172: 993-1000. 10.1093/infdis/172.4.993.CrossRefPubMed Shay DK, Maloney SA, Montecalvo M, Banerjee S, Wormser GP, Arduino MJ, Bland LA, Jarvis WR: Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis. 1995, 172: 993-1000. 10.1093/infdis/172.4.993.CrossRefPubMed
12.
go back to reference Peset V, Tallon P, Sola C, Sanchez E, Sarrion A, Perez-Belles C, Vindel A, Canton E, Gobernado M: Epidemiological, microbiological, clinical, and prognostic factors of bacteremia caused by high-level vancomycin-resistant Enterococcus species. Eur J Clin Microbiol Infect Dis. 2000, 19: 742-749. 10.1007/s100960000360.CrossRefPubMed Peset V, Tallon P, Sola C, Sanchez E, Sarrion A, Perez-Belles C, Vindel A, Canton E, Gobernado M: Epidemiological, microbiological, clinical, and prognostic factors of bacteremia caused by high-level vancomycin-resistant Enterococcus species. Eur J Clin Microbiol Infect Dis. 2000, 19: 742-749. 10.1007/s100960000360.CrossRefPubMed
13.
go back to reference Bhavnani SM, Drake JA, Forrest A, Deinhart JA, Jones RN, Biedenbach DJ, Ballow CH: A nationwide, multicenter, case–control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis. 2000, 36: 145-158. 10.1016/S0732-8893(99)00136-4.CrossRefPubMed Bhavnani SM, Drake JA, Forrest A, Deinhart JA, Jones RN, Biedenbach DJ, Ballow CH: A nationwide, multicenter, case–control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis. 2000, 36: 145-158. 10.1016/S0732-8893(99)00136-4.CrossRefPubMed
14.
go back to reference Vergis EN, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Linden PK, Wagener MM, Schmitt B, Muder RR: Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Ann Intern Med. 2001, 135 (7): 484-492. 10.7326/0003-4819-135-7-200110020-00007.CrossRefPubMed Vergis EN, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Linden PK, Wagener MM, Schmitt B, Muder RR: Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Ann Intern Med. 2001, 135 (7): 484-492. 10.7326/0003-4819-135-7-200110020-00007.CrossRefPubMed
15.
go back to reference Roghmann M-C, McCarter RJ, Brewrink J, Cross AS, Morris JG: Clostridium difficile infection is a risk factor for bacteremia due to vancomycin-resistant Enterococci (VRE) in VRE-colonized patients with acute leukemia. Clin Infect Dis. 1997, 25: 1056-1059. 10.1086/516112.CrossRefPubMed Roghmann M-C, McCarter RJ, Brewrink J, Cross AS, Morris JG: Clostridium difficile infection is a risk factor for bacteremia due to vancomycin-resistant Enterococci (VRE) in VRE-colonized patients with acute leukemia. Clin Infect Dis. 1997, 25: 1056-1059. 10.1086/516112.CrossRefPubMed
16.
go back to reference Stosor V, Peterson LR, Postelnick M, Noskin GA: Enterococcus faecium bacteremia: does vancomycin resistance make a difference?. Arch Intern Med. 1998, 158: 522-527. 10.1001/archinte.158.5.522.CrossRefPubMed Stosor V, Peterson LR, Postelnick M, Noskin GA: Enterococcus faecium bacteremia: does vancomycin resistance make a difference?. Arch Intern Med. 1998, 158: 522-527. 10.1001/archinte.158.5.522.CrossRefPubMed
17.
go back to reference Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD: Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis. 1998, 26: 1127-1133. 10.1086/520311.CrossRefPubMed Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD: Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis. 1998, 26: 1127-1133. 10.1086/520311.CrossRefPubMed
18.
go back to reference Kuehnert MJ, Jernigan JA, Pullen AL, Rimland D, Jarvis WR: Association between mucositis severity and vancomycin-resistant enterococcal bloodstream infection in hospitalized cancer patients. Infect Control Hosp Epidemiol. 1999, 20: 660-663. 10.1086/501561.CrossRefPubMed Kuehnert MJ, Jernigan JA, Pullen AL, Rimland D, Jarvis WR: Association between mucositis severity and vancomycin-resistant enterococcal bloodstream infection in hospitalized cancer patients. Infect Control Hosp Epidemiol. 1999, 20: 660-663. 10.1086/501561.CrossRefPubMed
19.
go back to reference Lautenbach E, Bilker WB, Brennan PJ: Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol. 1999, 20: 318-323. 10.1086/501624.CrossRefPubMed Lautenbach E, Bilker WB, Brennan PJ: Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol. 1999, 20: 318-323. 10.1086/501624.CrossRefPubMed
20.
go back to reference Zaas A, Song X, Tucker P, Perl T: Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant Enterococci. Clin Infect Dis. 2002, 35: 1139-1146. 10.1086/342904.CrossRefPubMed Zaas A, Song X, Tucker P, Perl T: Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant Enterococci. Clin Infect Dis. 2002, 35: 1139-1146. 10.1086/342904.CrossRefPubMed
21.
go back to reference de Perio MA, Yarnold Paul R, Warren J, Noskin Gary A: Risk factors and outcomes associated with non–Enterococcus faecalis, non–Enterococcus faecium enterococcal bacteremia. Infect Contr Hosp Epidemiol. 2006, 27: 28-33. 10.1086/500000.CrossRef de Perio MA, Yarnold Paul R, Warren J, Noskin Gary A: Risk factors and outcomes associated with non–Enterococcus faecalis, non–Enterococcus faecium enterococcal bacteremia. Infect Contr Hosp Epidemiol. 2006, 27: 28-33. 10.1086/500000.CrossRef
22.
go back to reference Olivier C, Blake R, Steed L, Salgado C: Risk of vancomycin-resistant Enterococcus (VRE) bloodstream infection among patients colonized with VRE. Infect Control Hosp Epidemiol. 2008, 29: 404-409. 10.1086/587647.CrossRefPubMed Olivier C, Blake R, Steed L, Salgado C: Risk of vancomycin-resistant Enterococcus (VRE) bloodstream infection among patients colonized with VRE. Infect Control Hosp Epidemiol. 2008, 29: 404-409. 10.1086/587647.CrossRefPubMed
23.
go back to reference Morris JG, Shay DK, Hebden JN, McCarter RJ, Perdue BE, Jarvis W, Johnson JA, Dowling TC, Polish LB, Schwalbe RS: Enterococci resistant to multiple antimicrobial agents, including vancomycin: establishment of endemicity in a university medical center. Ann Intern Med. 1995, 123: 250-259. 10.7326/0003-4819-123-4-199508150-00002.CrossRefPubMed Morris JG, Shay DK, Hebden JN, McCarter RJ, Perdue BE, Jarvis W, Johnson JA, Dowling TC, Polish LB, Schwalbe RS: Enterococci resistant to multiple antimicrobial agents, including vancomycin: establishment of endemicity in a university medical center. Ann Intern Med. 1995, 123: 250-259. 10.7326/0003-4819-123-4-199508150-00002.CrossRefPubMed
24.
go back to reference Papanicolaou G, Meyers B, Meyers J, Mendelson M, Lou W, Emre S, Sheiner P, Miller C: Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis. 1996, 23: 760-766. 10.1093/clinids/23.4.760.CrossRefPubMed Papanicolaou G, Meyers B, Meyers J, Mendelson M, Lou W, Emre S, Sheiner P, Miller C: Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis. 1996, 23: 760-766. 10.1093/clinids/23.4.760.CrossRefPubMed
25.
go back to reference Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW: Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis. 1996, 23: 767-772. 10.1093/clinids/23.4.767.CrossRefPubMed Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW: Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis. 1996, 23: 767-772. 10.1093/clinids/23.4.767.CrossRefPubMed
26.
go back to reference Carmeli Y, Eliopoulos GM, Samore MH: Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis. 2002, 8: 802-807. 10.3201/eid0808.010418.CrossRefPubMedPubMedCentral Carmeli Y, Eliopoulos GM, Samore MH: Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis. 2002, 8: 802-807. 10.3201/eid0808.010418.CrossRefPubMedPubMedCentral
27.
go back to reference Chavers LS, Moser SA, Funkhouser E, Benjamin WH, Chavers P, Stamm AM, Waites KB: Association between antecedent intravenous antimicrobial exposure and isolation of vancomycin-resistant Enterococci. Microb Drug Resist. 2003, 9: S69-S77. 10.1089/107662903322541928.CrossRefPubMed Chavers LS, Moser SA, Funkhouser E, Benjamin WH, Chavers P, Stamm AM, Waites KB: Association between antecedent intravenous antimicrobial exposure and isolation of vancomycin-resistant Enterococci. Microb Drug Resist. 2003, 9: S69-S77. 10.1089/107662903322541928.CrossRefPubMed
28.
go back to reference Nguyen GC, Leung W, Weizman AV: Increased risk of vancomycin-resistant Enterococcus (VRE) infection among patients hospitalized for inflammatory bowel disease in the United States. Inflamm Bowel Dis. 2011, 17: 1338-1342. 10.1002/ibd.21519.CrossRefPubMed Nguyen GC, Leung W, Weizman AV: Increased risk of vancomycin-resistant Enterococcus (VRE) infection among patients hospitalized for inflammatory bowel disease in the United States. Inflamm Bowel Dis. 2011, 17: 1338-1342. 10.1002/ibd.21519.CrossRefPubMed
29.
go back to reference McKinnell JA, Kunz DF, Chamot E, Patel M, Shirley RM, Moser SA, Baddley JW, Pappas PG, Miller LG: Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage. Infect Control Hosp Epidemiol. 2012, 33: 718-724. 10.1086/666331.CrossRefPubMed McKinnell JA, Kunz DF, Chamot E, Patel M, Shirley RM, Moser SA, Baddley JW, Pappas PG, Miller LG: Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage. Infect Control Hosp Epidemiol. 2012, 33: 718-724. 10.1086/666331.CrossRefPubMed
30.
go back to reference Worth LJ, Thursky KA, Seymour JF, Slavin MA: Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Haematol. 2007, 79: 226-233. 10.1111/j.1600-0609.2007.00911.x.CrossRefPubMed Worth LJ, Thursky KA, Seymour JF, Slavin MA: Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Haematol. 2007, 79: 226-233. 10.1111/j.1600-0609.2007.00911.x.CrossRefPubMed
31.
go back to reference Peel T, Cheng AC, Spelman T, Huysmans M, Spelman D: Differing risk factors for vancomycin-resistant and vancomycin-sensitive enterococcal bacteraemia. Clin Microbiol Infect. 2011, 18: 388-394.CrossRefPubMed Peel T, Cheng AC, Spelman T, Huysmans M, Spelman D: Differing risk factors for vancomycin-resistant and vancomycin-sensitive enterococcal bacteraemia. Clin Microbiol Infect. 2011, 18: 388-394.CrossRefPubMed
32.
go back to reference Patel R: Clinical impact of vancomycin-resistant Enterococci. J Antimicrob Chemother. 2003, 51 (iii): 13-21. Patel R: Clinical impact of vancomycin-resistant Enterococci. J Antimicrob Chemother. 2003, 51 (iii): 13-21.
33.
go back to reference Kaye KS, Harris AD, Samore M, Carmeli Y: The case-case–control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Contr Hosp Epidemiol. 2005, 26: 346-351. 10.1086/502550.CrossRef Kaye KS, Harris AD, Samore M, Carmeli Y: The case-case–control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Contr Hosp Epidemiol. 2005, 26: 346-351. 10.1086/502550.CrossRef
34.
go back to reference Barrall DT, Kenney PR, Slotman GJ, Burchard KW: Enterococcal bacteremia in surgical patients. Arch Surg. 1985, 120: 57-63. 10.1001/archsurg.1985.01390250049008.CrossRefPubMed Barrall DT, Kenney PR, Slotman GJ, Burchard KW: Enterococcal bacteremia in surgical patients. Arch Surg. 1985, 120: 57-63. 10.1001/archsurg.1985.01390250049008.CrossRefPubMed
35.
go back to reference Pallares R, Pujol M, Pena C, Ariza J, Martin R, Gudiol F: Cephalosporins as risk factor for nosocomial Enterococcus faecalis bacteremia: a matched case–control study. Arch Intern Med. 1993, 153: 1581-1586. 10.1001/archinte.1993.00410130103010.CrossRefPubMed Pallares R, Pujol M, Pena C, Ariza J, Martin R, Gudiol F: Cephalosporins as risk factor for nosocomial Enterococcus faecalis bacteremia: a matched case–control study. Arch Intern Med. 1993, 153: 1581-1586. 10.1001/archinte.1993.00410130103010.CrossRefPubMed
36.
go back to reference Mikulska M, Del Bono V, Prinapori R, Boni L, Raiola A, Gualandi F, Van Lint M, Dominietto A, Lamparelli T, Cappellano P, Bacigalupo A, Viscoli C: Risk factors for enterococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2010, 12: 505-512. 10.1111/j.1399-3062.2010.00544.x.CrossRefPubMed Mikulska M, Del Bono V, Prinapori R, Boni L, Raiola A, Gualandi F, Van Lint M, Dominietto A, Lamparelli T, Cappellano P, Bacigalupo A, Viscoli C: Risk factors for enterococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2010, 12: 505-512. 10.1111/j.1399-3062.2010.00544.x.CrossRefPubMed
37.
go back to reference Gray J, Marsh PJ, Stewart D, Pedler SJ: Enterococcal bacteraemia: a prospective study of 125 episodes. J Hosp Infect. 1994, 27: 179-186. 10.1016/0195-6701(94)90125-2.CrossRefPubMed Gray J, Marsh PJ, Stewart D, Pedler SJ: Enterococcal bacteraemia: a prospective study of 125 episodes. J Hosp Infect. 1994, 27: 179-186. 10.1016/0195-6701(94)90125-2.CrossRefPubMed
38.
go back to reference Caballero-Granado FJ, Becerril B, Cisneros JM, Cuberos L, Moreno I, Pachon J: Case–control study of risk factors for the development of enterococcal bacteremia. Eur J Clin Microbiol Infect Dis. 2001, 20: 83-90.PubMed Caballero-Granado FJ, Becerril B, Cisneros JM, Cuberos L, Moreno I, Pachon J: Case–control study of risk factors for the development of enterococcal bacteremia. Eur J Clin Microbiol Infect Dis. 2001, 20: 83-90.PubMed
39.
go back to reference Sitges-Serra A, Lopez M, Girvent M, Almirall S, Sancho J: Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg. 2002, 89: 361-367. 10.1046/j.0007-1323.2001.02023.x.CrossRefPubMed Sitges-Serra A, Lopez M, Girvent M, Almirall S, Sancho J: Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg. 2002, 89: 361-367. 10.1046/j.0007-1323.2001.02023.x.CrossRefPubMed
40.
go back to reference Patel R, Badley AD, Larson-Keller J, Harmsen WS, Ilstrup DM, Wiesner RH, Steers JL, Krom RA, Portela D, Cockerill FR, Paya CV: Relevance and risk factors of enterococcal bacteremia following liver transplantation. Transplantation. 1996, 61: 1192-1197. 10.1097/00007890-199604270-00013.CrossRefPubMed Patel R, Badley AD, Larson-Keller J, Harmsen WS, Ilstrup DM, Wiesner RH, Steers JL, Krom RA, Portela D, Cockerill FR, Paya CV: Relevance and risk factors of enterococcal bacteremia following liver transplantation. Transplantation. 1996, 61: 1192-1197. 10.1097/00007890-199604270-00013.CrossRefPubMed
41.
go back to reference Dutka-Malen S, Evers S, Courvalin P: Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol. 1995, 33: 24-27.PubMedPubMedCentral Dutka-Malen S, Evers S, Courvalin P: Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol. 1995, 33: 24-27.PubMedPubMedCentral
42.
go back to reference McGregor JC, Perencevich EN, Furuno JP, Langenberg P, Flannery K, Zhu J, Fink JC, Bradham DD, Harris AD: Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections. J Clin Epidemiol. 2006, 59: 1266-1273. 10.1016/j.jclinepi.2006.01.016.CrossRefPubMed McGregor JC, Perencevich EN, Furuno JP, Langenberg P, Flannery K, Zhu J, Fink JC, Bradham DD, Harris AD: Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections. J Clin Epidemiol. 2006, 59: 1266-1273. 10.1016/j.jclinepi.2006.01.016.CrossRefPubMed
43.
go back to reference Pregibon D: Goodness of link tests for generalized linear models. J Roy Stat Soc C Appl Stat. 1980, 29: 15-24. Pregibon D: Goodness of link tests for generalized linear models. J Roy Stat Soc C Appl Stat. 1980, 29: 15-24.
44.
go back to reference Suppola JP, Kuikka A, Vaara M, Valtonen VV: Comparison of risk factors and outcome in patients with Enterococcus faecalis vs Enterococcus faecium bacteraemia. Scand J Infect Dis. 1998, 30: 153-157. 10.1080/003655498750003546.CrossRefPubMed Suppola JP, Kuikka A, Vaara M, Valtonen VV: Comparison of risk factors and outcome in patients with Enterococcus faecalis vs Enterococcus faecium bacteraemia. Scand J Infect Dis. 1998, 30: 153-157. 10.1080/003655498750003546.CrossRefPubMed
45.
go back to reference Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, Hutton-Thomas RA, Whalen CC, Bonomo RA, Rice LB: Effect of antibiotic therapy on the density of vancomycin-resistant Enterococci in the stool of colonized patients. New Engl J Med. 2000, 343: 1925-1932. 10.1056/NEJM200012283432604.CrossRefPubMedPubMedCentral Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, Hutton-Thomas RA, Whalen CC, Bonomo RA, Rice LB: Effect of antibiotic therapy on the density of vancomycin-resistant Enterococci in the stool of colonized patients. New Engl J Med. 2000, 343: 1925-1932. 10.1056/NEJM200012283432604.CrossRefPubMedPubMedCentral
46.
go back to reference Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, Lee YJ, Dubin KA, Socci ND, Viale A, Perales MA, Jenq RR, van den Brink MR, Pamer EG: Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012, 55: 905-914. 10.1093/cid/cis580.CrossRefPubMedPubMedCentral Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, Lee YJ, Dubin KA, Socci ND, Viale A, Perales MA, Jenq RR, van den Brink MR, Pamer EG: Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012, 55: 905-914. 10.1093/cid/cis580.CrossRefPubMedPubMedCentral
47.
go back to reference Harris A, Samore M, Lipsitch M, Kaye K, Perencevich E, Carmeli Y: Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis. 2002, 34: 1558-1563. 10.1086/340533.CrossRefPubMed Harris A, Samore M, Lipsitch M, Kaye K, Perencevich E, Carmeli Y: Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis. 2002, 34: 1558-1563. 10.1086/340533.CrossRefPubMed
48.
go back to reference Timmers GJ, van der Zwet WC, Simoons-Smit IM, Savelkoul PH, Meester HH, Vandenbroucke-Grauls CM, Huijgens PC: Outbreak of vancomycin-resistant Enterococcus faecium in a haematology unit: risk factor assessment and successful control of the epidemic. Br J Haematol. 2002, 116: 826-833. 10.1046/j.0007-1048.2002.03339.x.CrossRefPubMed Timmers GJ, van der Zwet WC, Simoons-Smit IM, Savelkoul PH, Meester HH, Vandenbroucke-Grauls CM, Huijgens PC: Outbreak of vancomycin-resistant Enterococcus faecium in a haematology unit: risk factor assessment and successful control of the epidemic. Br J Haematol. 2002, 116: 826-833. 10.1046/j.0007-1048.2002.03339.x.CrossRefPubMed
49.
go back to reference Sedgwick P: Case–control studies: sources of bias. BMJ. 2011, 343: d6284-10.1136/bmj.d6284.CrossRef Sedgwick P: Case–control studies: sources of bias. BMJ. 2011, 343: d6284-10.1136/bmj.d6284.CrossRef
Metadata
Title
Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia
Authors
Agnes Loo Yee Cheah
Trisha Peel
Benjamin P Howden
Denis Spelman
M Lindsay Grayson
Roger L Nation
David CM Kong
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2014
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-14-353

Other articles of this Issue 1/2014

BMC Infectious Diseases 1/2014 Go to the issue